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1136-85 Ischemic Preconditioning Increases Heat Shock 
Protein-72 Protein Expression and Reduces Elevation of 
Creatine Kinase-MB Following Coronary Artery Bypass 
Graft in Humans
Christian Vahlhaus, Joachim Neumann², Tonny D. Tjan³, Frauke Janssen³, Hans H. 
Scheld³, Wilhelm Schmitz², Günter Breithardt, Thomas Wichter, University of Muenster, 
Muenster, Germany
Background: Ischemic preconditioning, ie, the reduction of infarct size development dur-
ing prolonged and severe myocardial ischemia by one or more preceding short episodes
of ischemia and reperfusion, is the most powerful endogenous cardioprotective effect.
We investigated whether a stress activated signal-transduction via heat shock protein 72
(HSP-72) mediated phopshorylation of p38 Mitogen activated protein kinase (MAPK) is
involved in the creatine kinase-MB (CKMB) release reducing effect of ischemic precondi-
tioning in patients undergoing CABG.
Methods: According to the ischemic episodes within 24-48 hours before CABG patients
with angina CCS III or IV were classified as preconditioned (IP, n=9), whereas patients
with angina CCS I or II formed the control group (CON, n=10). The effect of IP on the
CABG induced maximal CKMB-release was examined. Biopsies from ischemic and con-
trol regions in each patient were processed to analyse protein expression of HSP-72 and
the calcium handling proteins phospholamban (PL), sarcoendoplasmic Ca-ATPase 2a
(SERCA), calsequestrin (CSQ), the inhibitory subunit of troponin (TnI) and phosphoryla-
tion of MAPK.
Results: IP reduced CKMB (18.7±1.3 vs. 13.8±1.5 U/L, CON vs. IP, mean±SD, p=0.02).
Results of biopsy specimens are depicted in table 1 (relative changes of *protein expres-
sion and #MAPK-phosphorylation).
Conclusion: Cardioprotection during CABG can be improved with IP. Possible mecha-
nisms are the induced expression of HSP-72 and/or SERCA.
1136-86 Protein Kinase C Epsilon Is Upstream and Protein 
Kinase C Alpha Is Downstream of MitoKATP Channels 
in the Signaling of Ischemic Preconditioning in the 
Human Myocardium
Ashraf Hassouna, Bashir M. Matata, Manuel Galiñanes, University of Leicester, 
Leicester, United Kingdom
Background: PKC is part of the signal transduction of ischemic preconditioning (IPC)
but the PKC isoforms involved and their relation to mitoKATP channels is unclear. Meth-
ods: Right atrial muscles from patients undergoing cardiac surgery were sectioned and
after equilibration were randomized to receive one of the following protocols: aerobic con-
trol (A/C), simulated ischemia for 90 min and reoxygenation for 120 min (SI/R), IPC using
5 min SI/ 5 min R and the following inhibitors were added 10 min before and during IPC:
V1-2 peptide [10 µM], GO6976 [100 nM], Rottlerin [100 µM], and LY333531 [100 nM] for
PKCε, α, δ, β respectively. To investigate the location of the PKC isoforms involved in IPC
in relation to mitoKATP channels, PKC α and ε inhibitors were added 10 min before and
during preconditioning by Diazoxide (DXZ)[100 µM] in a second experiment. CK leakage
and MTT cell viability were measured. Phosphorylation of PKC isoforms were measured
using immunoblots after treatment with IPC or DXZ. Results: In Fig, PKCε and α inhibi-
tors blocked IPC whereas PKCδ and β inhibitor did not. The protection elicited by
mitoKATP channels opening with DXZ was blocked by the inhibition by PKCα but not by
inhibition of PKCε isoforms. The MTT values mirrored the CK results. In addition, DXZ
caused increased phosphorylation of PKCα similar to IPC but failed to cause significant
increase of PKCε phosphorylation. Conclusion: Both PKCε and α are involved in IPC of
the human myocardium with PKCε upstream and PKCα downstream of mitoKATP chan-
nels.
1136-87 Remote Preconditioning by Infrarenal Occlusion of the 
Aorta Protects the Rat Heart From Infarction by a 
Molecular Mechanism Involving Free Radicals and a p38 
Mitogen Activated Protein Kinase Activation
Christof Weinbrenner, Alexander Werschy, Falk Schulze, Ruth H. Strasser, University of 
Technology, Dresden, Germany
Background: Ischemic preconditioning (PC) is a powerful mechanism in reducing the
infarct size of the heart. Protection can be provided either by an ischemic stimulus of the
heart itself (classical or orthotopic PC) or by ischemia of an organ distant to the heart
(remote or heterotopic PC).
Objective and methods: To address the question whether remote PC is dependent on
endogenously released free radicals and/or on an activation of p38 MAPK, infarct size
was determined in an in situ model of infrarenal occlusion of the aorta (IOA) in the rat
after pharmacological inhibition of free radicals or p38 MAPK.
Results: Control hearts (30 min regional ischemia followed by 30 min of reperfusion) had
an infarct size of 50±2%, whereas classical PC with one ischemia/reperfusion cycle (I/R)
reduced it to 21±4% and with three I/R cycles to 14±1% of the risk zone (p<0.001). 15
min IOA followed by a 10 min reperfusion period reduced the infarct size to 20±3%
(p<0.001 vs. control; p=0.051 vs. PC three I/R cycles).
20 mg/kg body weight MPG, a free radical scavenger, completely blocked the protection
obtained by IOA (46±3%, p<0.001 vs. IOA no MPG) as well as the one obtained by clas-
sical PC with one I/R cycle (43±4%, p<0.01 vs. PC one I/R cycle no MPG). Protection of
classical PC with three I/R cycles could, however, not be blocked (13±4%). MPG itself
had no influence on infarct size in control hearts (53±5%).
Using SB203580, a selective p38 MAPK-inhibitor, at a dose of 2 mg/kg body weight, pro-
tection by remote PC was blocked (46±3%, p<0.001 vs. IOA no SB) as well as by classi-
cal PC with three I/R cycles (42±4%, p<0.001 vs. PC no SB). Again SB itself had no
influence on infarct size in control hearts (47±3%).
Conclusion: Protection of the heart by heterotopic PC using IOA is nearly as powerful as
orthotopic preconditioning. Both protection methods share as common elements in their
signal transduction pathways free radicals and p38 MAPK. Since orthotopic PC by one I/
R cycle but not by three I/R cycles could be blocked by MPG, protection by orthotopic PC
is more robust than protection by heterotopic PC. The protecting substances, which are
located upstream of p38 MAPK, could be free radicals but remain to be characterized fur-
ther.
1136-88 The Polymorphisms C (-260) T in the Promoter Region 
of CD14 Receptor Gene and G (-174) C of Interleukin-6 
Gene Are Not Related to the Immune Response to 
Chlamydia Pneumoniae Infection and Heat Shock 
Protein-60 in Ischaemic Heart Disease
Giovanna Di Giannuario, Luigi M. Biasucci, Alessandra Ciervo, Giovanna Liuzzo, Matteo 
Santamaria, Maddalena Piro, Salvatore Brugaletta, Antonio Cassone, Antonio Cassone, 
Pierfranco Pignatti, Filippo Crea, Catholic University, Rome, Italy, Istituto Superiore 
Sanita', Rome, Italy
Background: The conflicting results on the role of Chlamydia pneumoniae (Cp) in
ischaemic heart disease might be related to modulation of individual response to Cp-
infection by genetic polymorphisms. The CD14 membrane receptor is a mediator for
monocyte activation by bacterial products, as lypopolysaccharide and Chlamydial Heat
Shock Protein 60 (HSP60Cp). Interleukin 6 is a pro-inflammatory cytokine stimulating B-
lymphocytes differentiation and antibody production. The aim of this study was to evalu-
ate if two functional genetic polymorphisms, the C (-260) T polymorphism in the promoter
region of the CD14 receptor gene and the G (-174) C polymorphism of interleukin 6
gene, are related to immune response to Cp in patients with IHD. Methods: we studied 51
patients with IHD. In all patients we measured serum levels of Antibody anti-HSP60Cp
(AbHSP60) (ELISA) and IgG anti Cp. The polymorphisms C (-260) T of CD14 receptor
gene and G (-174) C of Interleukin 6 gene were detected by polymerase chain reaction
and restriction analysis. Results: We did not find significant differences in AbHSP60
serum SD) among the C (-260) T polymorphisms of the CD14 receptor ± levels (AU;
mean 0.42, 0.63 ± gene: CC homozygotes, CT heterozygotes, and TT homozygotes
(0.66 0.46, respectively; p=ns). No differences were also found among the ± 0.37, 0.77 ±
three genotypes of G (-174) C Interleukin 6 gene polymorphism: GG homozygotes, 0.37,
± 0.42, 0.58 ± 0.37, 0.74 ± GC heterozygotes and CC homozygotes (0.62 respectively;
p=ns). IgG anti Cp levels (median, range), were not significantly different between the
three genotypes of C (-260) T CD14 receptor gene polymorphism, CC homozygotes, CT
heterozygotes and TT homozygotes (24, 0-128; 48, 0-256; 8, 0-32, respectively; p=ns)
and between the three genotypes of G (-174) C Interleukin 6 gene polymorphism: GG
Gene Hibernating LAD/normal
3 Months 5 Months
Collagen Type I
2.8 ± 0.7* 1.3 ± 0.2†
Collagen Type III 2.2 ± 0.5* 1.4 ±0.2
Collagen Type VI 1.5 ± 0.2* 0.9 ± 0.1†
Fibronectin 4.9 ± 2.7* 1.3 ± 0.2
Vimentin 1.8 ± 0.3* 1.2 ± 0.1†
GAPDH 0.9 ± 0.2 0.9 ± 0.1
*LAD vs. normal p<0.05; mean ± SEM
† 5 vs. 3 Months p< 0.05, Statistical Analysis of Microarray
Table 1: Biopsy specimens
mean±SD PL*  SERCA*  CSQ*  TnI*  HSP-72*  MAPK#
CON 0.24±0.12 -0.26±0.07 -0.09±0.04 -0.12±0.07 0.09±0.12 0.05±0.28
IP 0.06±0.35 0.33±0.19 -0.02±0.07 0.12±0.18 0.44±0.11 0.84±0.43
t-test: P 0.626 0.008 0.354 0.212 0.045 0.141
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homozygotes, GC heterozygotes and CC homozygotes (16, 0-256; 32, 0-256; 32, 0-64,
respectively; p=ns). Conclusion: Our data suggest that the C (-260) T polymorphism in
the promoter region of the CD14 receptor gene and the G (-174) C polymorphism of the
Interleukin 6 gene, are not involved in modulation of the individual immune response to
Cp infection in patients with ischaemic heart disease.
1136-89 ßeta-2 Receptors Are Upregulated in Canine Ventricles 
With a Chronic Myocardial Infarction
Philip B. Adamson, Travis Kanaly, Emilio Vanoli, Jennifer Suarez, Jeffrey Ardell, 
University of Oklahoma Health Sciences Center, Oklahoma City, OK, East Tennessee 
State University, Johnson City, TN
Background: Beta-1-adrenergic receptor densities decrease in end-stage cardiomyopa-
thy with no significant change in beta-2 or alpha receptor density. The relative densities of
beta-receptors after myocardial infarction (MI) with normal left ventricular function are
less well understood. This study examined beta-receptor densities in normal dogs and
compared them with animals 45 days after MI.
Methods: Four dogs were instrumented with an anterior MI by permanent ligation of the
left anterior descending (LAD) coronary artery during lateral thoracotomy. 45 days were
allowed for recovery and ventricular tissue was harvested during a terminal experiment.
Tissue in the LAD distribution was compared with tissue in the circumflex (Cx) territory in
post-MI dogs and normal animals (n=15). beta-receptor densities were measured with
receptor specific quantitative film autoradiography.
Results: beta-receptors from normal animals were not different between the LAD (7.6±3
fmol/mg, 76% beta-1; 2.3±0.6 fmol/mg, 23%, beta-2) and Cx (7.1±0.8 fmol/mg, 75%
beta-1; 2.3±0.2 fmol/mg, 25%, beta-2) tissues. Beta-2 receptor densities in post-MI dogs
were higher (p<0.04) in both the LAD (7.4±2 fmol/mg, 63%, beta-1; 4.3±1 fmol/mg, 37%,
beta-2) and the Cx (5.6±2 fmol/mg, 54%, beta-1; 4.7±2 fmol/mg, 46%, beta-2) territories,
while beta-1 receptor densities did not change.
Conclusions: Beta-2 adrenergic receptor densities increase following chronic MI and
comprise a larger percentage of available adrenergic receptors in canine ventricles.
These data may help explain why nonselective beta-blockers tend to be more effective in
post-MI clinical populations
1136-90 Relation of the –174 G/C and –572 G/C Promoter 
Polymorphisms of the Interleukin-6 Gene to Interleukin-
6 and Highly Sensitive C-Reactive Protein Serum Levels 
and to the Extent of Infarction in Acute Myocardial 
Infarction
Atiye Cengel, Aycan F. Erkan, Mehmet Ali Ergun, Derya Kan, Sevda Menevse, Gazi 
University School of Medicine, Ankara, Turkey
Background: GG homozygotes for -174 G/C polymorphism and carriers of C allele for
572 G/C have higher interleukin-6 (IL-6) levels and longer hospital stays after surgical
coronary revascularization. Our aim was to test the hypothesis that promoter polymor-
phisms of the IL-6 gene may be associated with the extent of acute myocardial infarc-
tion(AMI), and the degree of immunological response in AMI.
Methods: We enrolled 50 patients with the diagnosis of AMI. Patients with inflammatory
or infectious conditions, malignancy, recent trauma or surgery were excluded. Serum IL-6
and C-Reactive Protein (CRP) levels were determined on admission, and at 48 and 72
hours. Deoxy-ribo nucleic acid was extracted from peripheral blood and amplified with
polymerase chain reaction. The -174 G/C and -572 G/C genotypes were determined by
using primers. Left ventricular ejection fraction and wall motion score index (WMSI) were
calculated on trans-thoracic echocardiography.
Results: There are no significant differences between the GG, GC, and CC groups of
both polymorphisms according to infarct localization, therapy, and basal characteristics .
Baseline CRP and IL-6 levels were not significantly different, but the 48- and 72-hour
CRP and IL-6 levels were significantly higher in -174 GG patients when compared to-174
GC and CC patients.
Ejection fraction was significantly lower and WMSI was significantly higher in -174 GG
patients when compared to -174 GC and CC patients.
There were no statistically significant differences between -572 GG and GC (there were
no CC ) patients according to serum IL-6 and CRP levels, ejection fraction,and WMSI.
Conclusion:
We have demonstrated that GG homozygosity for the -174 G/C polymorphism is associ-
ated with higher serum IL-6 and CRP levels, and more extensive infarction evidenced by
lower ejection fraction and higher WMSI in AMI. There was no association of the 572 G/C
polymorphism with these conditions.
All these associations were independent from factors such as age, gender, diabetes,
hypertension, cigarette smoking, prior use of aspirin or statins , infarct localization, ther-
apy, and catheter-based mechanical revascularization.
1136-91 Contribution of Genetic Characteristics of Vascular 
Adrenergic Receptor to Variant Angina
Sang-Ho Jo, Jae-Bin Seo, Shu-Ying Zhang, Jin-Sik Park, Young-Seok Cho, Jin-Ho Choi, 
Bon-Kwon Koo, Yong-Jin Kim, Seil Oh, In-Ho Chae, Hyo-Soo Kim, Dae-Won Sohn, 
Byung-Hee Oh, Myoung-Mook Lee, Young-Bae Park, Yun-Shik Choi, Seoul National 
University College of Medicine, Seoul, South Korea, Seoul National University Hospital, 
Seoul, South Korea
Background: The α2 or β2-adrenergic receptor in vasculature mediate vasoconstriction or
dilation respectively in response to adrenergic agents, and β1-adrenergic receptor in
heart mediates chronotrophic and inotrophic changes. We hypothesized that adrenergic
receptor gene polymorphism is associated with vasospastic angina, and would explain
the different prevalence of variant angina between Koreans and Caucasians. We investi-
gate the relationship of vasospastic angina and four kinds of adrenergic receptor poly-
morphisms (α2c Del322-325, β2 Gly16, β2 Glu27 and β1 Arg389)
Methods: Vasospastic angina (N=162) was confirmed by focal coronary spasm in CAG
with chest pain or ST elevation on ECG after ergonovine intravenous infusion. Normal
control group comprised 129 subjects who showed normal coronary angiogram. After a
diagnostic coronary angiography was performed, four kinds of genotypes were identified
separately using different PCR and RFLP methods from the DNA extracted from the
peripheral monocytes.
Results: The allele frequencies of four kinds of adrenergic receptor polymorphisms (α2c
Del322-325, β2 Gly16, β2 Glu27 and β1 Arg389) in normal control were 0.23, 0.69, 0.53
and 0.17 respectively, and these are different from those of Caucasians (0.04, 0.61, 0.43,
0.73). The differences were prominent in α2c Del322-325 and β1 Arg389. The frequen-
cies of homozygosity for α2c Del322-325 polymorphism were significantly higher in vari-
ant angina group than in control, 16.4% and 0.8% respectively (p<0.0001). The
homozygosity for β2 polymorphism of codon 27(Glu27) is much less frequent in variant
angina group than in control(29.3% : 49.3%, p<0.0001). However, there was no differ-
ence in the prevalence of β2 polymorphism of codon 16(Gly16) or β1 polymorphism
between the two groups.
Conclusion: The Del (322-325) mutant of α2-receptor is a new genetic risk factors for
variant angina, and the Glu27 allele of the β2-adrenergic receptor is a negative risk factor
for variant angina. This is the first report in the world to demonstrate the contribution of
genetic characteristics of the vascular adrenergic system to coronary vasospasm.
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1137-77 Long-Term Cost-Effectiveness of Clopidogrel in 
Patients Having Percutaneous Coronary Intervention 
Early After Acute Coronary Syndrome: Results From 
PCI-CURE
William S. Weintraub, Elizabeth M. Mahoney, Shamir Mehta, Andre Lamy, Yong Yuan, 
Roland Chen, Joseph Jackson, Sylvie Gabriel, Olivier Bouin, Julie Spiesser, Salim Yusuf, 
Emory University, Atlanta, GA, McMaster University, Hamilton, ON, Canada
Background: The efficacy of clopidogrel up to 1 year after percutaneous coronary inter-
vention (PCI) following non-ST-elevation acute coronary syndrome (ACS) was demon-
strated in PCI-CURE.
Methods: We evaluated long-term cost effectiveness of clopidogrel after PCI during the
initial hospitalization in PCI-CURE; patients received clopidogrel pre-treatment (n=821)
or placebo (n=909). After PCI, >80% received open-label ADP-receptor antagonist for ~
4 weeks, then study drug for up to 1 year. This PCI-CURE subgroup characterizes US
PCI practice pattern. The composite CV death, stroke or MI occurred in 76 (9.3%) clopi-
dogrel vs 116 (12.8%) placebo patients (RR 0.73, p=0.02). Hospitalizations were
assigned a DRG; costs were estimated from: 1) Medicare, 2) MEDSTAT (private insur-
ance) , 3) MEDSTAT age <65 and Medicare age >65. Clopidogrel was assigned a cost of
$3.22/day. Lost life expectancy associated with CV death, MI and stroke was estimated
from Framingham data, discounted 3%. 95% CIs for costs differences were obtained by
bootstrap.
Results: 
The incremental cost-effectiveness ratio was $882/life year gained (LY) with Medicare
(37.6% dominant, 4.8% dominated, 90.8% <$50,000/LY), dominant with MEDSTAT
(58.1% dominant, 3.3% dominated, 91.7% <$50,000/LY), dominant with MEDSTAT/Medi-
care (56.0% dominant, 3.6% dominated, 92.0% <$50,000/LY).
Conclusions: Long-term clopidogrel therapy, up to 1 year after early PCI in the setting of
ACS, is both effective and highly cost-effective in cost per LY gained.
1137-93 Carvedilol Preserves Cellular Integrity and Improves 
Outcome in Patients With Chronic Hibernating 
Myocardium After Revascularization
Ernst R. Schwarz, Tuphoung Diep, Erik C. Skobel, Bernd Nowak, Sawa Kostin, Beate 
Grohmann, The University of Texas Medical Branch, Galveston, TX, Rheinisch 
Westfaelische-Technische Hochschule, Aachen, Germany
Chronic hibernating myocardium (HM) might undergo progressive cellular degeneration
and replacement fibrosis due to apoptosis and necrosis in the setting of recurrent myo-
cardial ischemia. Carvedilol has been shown to provide anti-oxidant and anti-apoptotic
effects in experimental animal studies in addition to its alpha- and beta-blocking effects.
Clopidogrel Placebo Difference 95% CI
Medicare Cost $14,856 $14,765 $91 -$713, $839
MEDSTAT Cost $20,195 $20,377 -$182 -$1,258, $837
MEDSTAT/Medicare $17,832 $17,987 -$155 -$1,131, $816
Lost Life Expectancy in 
Years (Framingham)
0.3426 0.4452 0.1027 -0.0452, 0.2581
